Excessive myeloproliferation in MPN is characterized by constitutive activation of JAK2/STAT3 signaling in MPN, while combined inhibition of PI3K/mammalian target of rapamycin (mTOR) and JAK2 signaling pathways reduces the extent of disease and prolonged survival [7]. The gene discussed is JAK2; the disease is myeloproliferative disorder.